Rezafungin: A Brief Notes to Know

Rezafungin is a novel long-acting echinocandin licensed by the US Food and Drug Administration for the treatment of invasive candidiasis and candidaemia. A novel inhibitor of -glucan synthase, rezafungin possesses a chemical relationship with anidulafungin. It is regarded as the original echinocandin molecule of the current generation. With improved tissue penetration, better pharmacokinetic, phamacodynamic (PK/PD) pharmaco-metrics, and an excellent safety profile, it offers a number of advantages over the FDA-approved echinocandins. Hypokalemia, pyrexia, diarrhea, anemia, vomiting, nausea, hypomagnesemia, stomach pain, constipation, and hypophosphatemia are the most frequent side events of this medicine (incidence 5%). Because of its remarkable half-life, rezafungin is a promising new addition to the antifungal toolbox that may be used as prophylaxis in immunocompromised patients and early hospital discharge for stable patients. This study provides a brief description of the mechanism of action, target, side effect, and metabolism data on rezafungin.